论文部分内容阅读
甲状腺髓样癌(MTC)的预后,关键取决于诊断时该病的程度和范围。早期阶段进行手术可获得较好的预后,然而对已有远隔转移的病人存活率很低,10年生存率一般在30％以下;化疗的结果更令人失望,几乎没有能根治的,仅30%呈局部反应,且常有许多副作用。因此,采用生长抑素(SRIF)类似物洽疗有症状的转移性MTC引起临床的极大兴趣。本文作者报告3例MTC患者接受SRIF类似物(SMS 201—995)长期治疗3～17个月。其中1例为散发型;2例为多发性内分泌瘤(MEN)Ⅱa. SMS 201—995经皮下注射给药,用自动泵,开
The prognosis of medullary thyroid carcinoma (MTC) depends critically on the extent and extent of the disease at the time of diagnosis. Early stage surgery can achieve better prognosis. However, the survival rate of patients with distant metastases is very low, the 10-year survival rate is generally below 30%; the results of chemotherapy are even more disappointing, and almost no cure, only 30% is a local reaction and often has many side effects. Therefore, the use of somatostatin (SRIF) analogues for the treatment of symptomatic metastatic MTC causes great clinical interest. The authors report 3 cases of MTC patients receiving long-term treatment of SRIF analogs (SMS 201-995) for 3 to 17 months. One case was sporadic; 2 cases were multiple endocrine tumors (MEN) IIa. SMS 201-995 was administered subcutaneously, using an automatic pump,